Department of Radiation Oncology, University of California, San Francisco, United States.
Department of Radiation Oncology, Massachusetts General Hospital, United States.
Crit Rev Oncol Hematol. 2023 Feb;182:103924. doi: 10.1016/j.critrevonc.2023.103924. Epub 2023 Jan 22.
Metaplastic breast cancer (MpBC) is an uncommon aggressive malignancy that is associated with a poor prognosis. Due to its rarity, the relationships between the clinical and pathological features of MpBC, treatment approach, and clinical outcomes remain underexplored. In the following review article, we synthesize the existing data on the clinical, pathological and genomic features, management, and outcomes of MpBC. We also identify potential targets for future clinical trials.
化生性乳腺癌（MpBC）是一种罕见的侵袭性恶性肿瘤，预后较差。由于其罕见性，MpBC 的临床和病理特征、治疗方法和临床结果之间的关系仍未得到充分探讨。在本篇综述文章中，我们综合了现有关于 MpBC 的临床、病理和基因组特征、治疗方法和结果的数据，并确定了未来临床试验的潜在靶点。
